Ginsenoside Rb3
(Synonyms: 人参皂苷 Rb3; Gypenoside IV) 目录号 : GN10220
A steroid glycoside with diverse biological activities
Cas No.:68406-26-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ginsenoside Rb3 is extracted from steamed Panax notoginseng. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.
Ginsenoside Rb3 (0.1-10 μM) is tested for inhibition of tumor necrosis factor-α (TNF)-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) luciferase reporter activity using a human kidney 293T cell-based assay. Ginsenoside Rb3 shows the significant activity with an IC50 of 8.2 μM. Ginsenoside Rb3 also inhibits the induction of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) messenger Ribonucleic acid (mRNA) in a dose-dependent manner after HepG2 cells have been treated with TNF-α (10 ng/mL)[1]. Ginsenoside Rb3 (0.1-10 μM) significantly increases cell viability and inhibits lactate dehydrogenase (LDH) release in a dose-dependent manner. PC12 cell viability as determined by MTT reduction is also markedly decreased after the cell is exposed to oxygen and glucose deprivation (OGD)/OGD-Rep. But, when the cells are pretreated with Ginsenoside Rb3 (0.1, 1, and 10 μM), OGD/OGD-Rep induced cell toxicity is significantly attenuated, which is concentration-dependently attenuated by Ginsenoside Rb3 treatment. The viabilities are raised to 52.8%±5.6%, 64.6%±5.7%, and 76.4%±8.8%, respectively, compared with the control group[2].
Ginsenosides Rb3 is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in ApcMin/+ mice. Six-weeks-old mice are subjected to Rb3 treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Rb3 treatments[3].
References:
[1]. He F, et al. Antitumor effects of dammarane-type saponins from steamed Notoginseng. Pharmacogn Mag. 2014 Jul;10(39):314-7.
[2]. Zhu JR, et al. Protective effects of ginsenoside Rb(3) on oxygen and glucose deprivation-induced ischemic injury in PC12 cells. Acta Pharmacol Sin. 2010 Mar;31(3):273-80.
[3]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in ApcMin/+ mice. Sci Rep. 2017 Oct 2;7(1):12552.
|
Kinase experiment: |
HepG2 cells are seeded at a concentration of 1×105 cells/mL (1.5 mL) in a 12-well plate and grown for 24 h. All cells are then transfected with Pnf-κB-luc plasmid (0.5 μg/well). Transfection are performed by the lipofectamine LTX. After 23 h of transfection, medium is changed to assay medium. After 24 h of transfection, cells are treated with test compounds (e.g., Ginsenoside Rb3; 0.1, 1 and 10 uM) for another 24 hours. After 25 h of transfection, cells are treated with 10 ng/mL of TNF-α for another 23 hours. The luciferase activity of cell lysates is assayed with 100 μL of by luciferase assay kit using an LB 953 Autolumat. Transfections are performed in triplicate, and activation is normalized against α-galactosidase activity[1]. |
|
Cell experiment: |
NGF-differentiated PC12 cells are plated at a density of 1.0×105 cells/mL 2 days before each experiment. To initiate OGD, the cell culture medium is removed and replaced with the glucose-free DMEM, then the cells are incubated at 37°C in an oxygen-free chamber (95% N2 and 5% CO2) for 4 h (OGD), and the change in oxygen levels of the culture medium are monitored during incubation in oxygen-free chamber. Following OGD, glucose is added to normal levels (final concentration: 4.5 mg/mL) and cells are incubated under normal growth conditions (95% air and 5% CO2) for additional 24 h as OGD-reperfusion (OGD-Rep). Ginsenoside Rb3 (0.1, 1, 10 μM) is added to the culture 24 h before OGD treatment and throughout the OGD reperfusion. The control culture is always maintained in normal DMEM and put in the incubator under normal conditions[2]. |
|
Animal experiment: |
Mice[3]Heterozygous male ApcMin/+ (C57BL/6J-ApcMin/+) mice are used. Total 32 male ApcMin/+ mice (aged 6 weeks) are divided into three groups; 10 mice in the control group and 22 mice equally divided for Rb3 and Rd treatments. The mice are daily gavage with a single dose of Ginsenoside Rb3 or Rd at 20 mg/kg, or solvent control. The treatments are carried out for 8 consecutive weeks. |
|
References: [1]. He F, et al. Antitumor effects of dammarane-type saponins from steamed Notoginseng. Pharmacogn Mag. 2014 Jul;10(39):314-7. |
|
| Cas No. | 68406-26-8 | SDF | |
| 别名 | 人参皂苷 Rb3; Gypenoside IV | ||
| 化学名 | Ginsenoside Rb3 | ||
| Canonical SMILES | CCC(=CCCC(C)(C1CCC2(C1C(CC3C2CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(CO8)O)O)O)O)O)O)C | ||
| 分子式 | C53H90O22 | 分子量 | 1079.26 |
| 溶解度 | ≥ 35.97mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9266 mL | 4.6328 mL | 9.2656 mL |
| 5 mM | 0.1853 mL | 0.9266 mL | 1.8531 mL |
| 10 mM | 0.0927 mL | 0.4633 mL | 0.9266 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet